Treatment of Schizoaffective Disorder Using Mifepristone

Phase 2/3 Terminated 12 enrolled Stanford University Pritzker Family Foundation · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.

Timeline

Start: 1998-04
Primary completion: 2009-05
Completion: 2009-05

Outcome

Missed primary endpoint

Stopped (Business): “Lack of funding.”

registry analysis (superiority or other test); Placebo vs Mifepristone; p = .812; Mixed Models Analysis NCT00725270 ↗

registry analysis (superiority or other test); Placebo vs Mifepristone; p = .203; eta sq .157; Mixed Models Analysis NCT00725270 ↗

Publications

Cherian K, Schatzberg AF, Keller J. HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition. Schizophr Res. 2019 Nov;213:72-79. doi: 10.1016/j.schres.2019.07.003. Epub 2019 Jul 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mifepristone	Small molecule	600 mg	—